Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the effi cacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here, we report the fi nal overall survival results from this study based on an unplanned second interim analysis.
Introduction
Advances in the understanding of the molecular pathology of renal cell carcinoma have led to the development of agents targeting the VEGFR and mTOR signalling pathways. First-line standard-of-care treatments for patients with advanced renal cell carcinoma are the VEGFR tyrosine-kinase inhibitors sunitinib and pazopanib. Second-line standard-of-care treatments include the VEGFR tyrosine-kinase inhibitors axitinib and sorafenib, the mTOR inhibitor everolimus, and the PD-1 checkpoint inhibitor nivolumab. [1] [2] [3] Few treatments have shown a survival benefi t, and none have shown an improvement in all three effi cacy endpoints of progression-free survival, objective response, and overall survival, compared with standard-of-care treatment in a randomised phase 3 trial in previously treated patients with renal cell carcinoma. Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. 4 Upregulation of MET and AXL in clear-cell renal cell carcinoma happens as a consequence of von Hippel-Lindau protein dysfunction, has been implicated in tumour progression and VEGFR tyrosine-kinase inhibitor resistance in preclinical studies, and has been associated with a poor prognosis in patients with renal cell carcinoma. [5] [6] [7] [8] [9] [10] The randomised phase 3 METEOR trial 11 compared the effi cacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Progression-free survival in the fi rst 375 randomised patients, the primary endpoint, was signifi cantly improved with cabozantinib compared with everolimus treatment with a median progression-free survival of 7·4 months (95% CI 5·6-9·1) versus 3·8 months (3·7-5·4; HR 0·58, 95% CI 0·45-0·75; p<0·001) as assessed by an independent radiology review committee. 11 Here we report the fi nal overall survival results from the METEOR study based on an unplanned second interim analysis. Analyses of progression-free survival and objective response in all randomised patients, and updated safety data are also reported.
Methods

Study design and participants
METEOR is a randomised, open-label, phase 3, study with patients enrolled at 173 hospital and outpatient clinics in 26 countries (appendix pp 2-5). 11 Patients 18 years or older with advanced or metastatic renal cell carcinoma and a clear-cell histology were eligible for enrolment if they had measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), 12 had received at least one previous VEGFR tyrosine-kinase inhibitor (there was no limit to the number of previous treatments), and had disease progression during or within 6 months of the most recent VEGFR tyrosine-kinase inhibitor treatment and within 6 months before randomisation. Patients were required to have a Karnofsky performance status score of at least 70% and adequate organ function, based on standard laboratory tests including haematology, serum chemistry, lipids, coagulation, thyroid function, and urinalysis. Patients with brain metastases were allowed provided these were stable and asymptomatic. Patients with previous mTOR inhibitor therapy, including everolimus, were not eligible for the study nor were patients with uncontrolled hypertension or clinically signifi cant cardiovascular, gastrointestinal, wound healing, or infectious comorbidities. The study adhered to the Good Clinical Practice guidelines and the Declaration of Helsinki. The institutional review board or ethics committee of the participating centres approved the study protocol. All patients provided written informed consent.
Randomisation and masking
Patients were randomly assigned (1:1) to receive either cabozantinib or everolimus. Randomisation was stratifi ed by the number of previous VEGFR tyrosinekinase inhibitor treatments (1 or ≥2) and Memorial Sloan Kettering Cancer Center (MSKCC) risk group (favourable, intermediate, or poor) for previously treated patients 13 (appendix p 6). We used stratifi ed permuted blocks as the See Online for appendix
Research in context
Evidence before this study In the randomised, phase 3 METEOR trial, treatment with cabozantinib, an inhibitor of tyrosine kinases including MET, VEGFR, and AXL, signifi cantly improved progression-free survival compared with treatment with everolimus in previously treated patients with advanced renal cell carcinoma. In a scientifi c literature review up to March 10, 2016, we searched PubMed with the search terms, phase 3, overall survival, ORR, PFS, RCC, AXL, MET, VEGFR, and TKI. None of the currently approved treatments had shown signifi cant benefi t for all three effi cacy endpoints of overall survival, progression-free survival, and objective response in a pivotal phase 3 trial in previously treated patients with advanced renal cell carcinoma. We also found data suggesting that increased expression of MET and AXL are associated with a poor prognosis in renal cell carcinoma patients, and that inhibition of these targets may help to overcome resistance to VEGF pathway inhibition.
Added value of this study
Our fi ndings show that treatment with cabozantinib was associated with a signifi cant increase in overall survival, in addition to an improvement in progression-free survival and objective response, when compared with treatment with everolimus, a second-line standard of care in patients with second-line advanced renal cell carcinoma. The recorded clinical benefi ts were consistent in all subgroups. The safety profi le of cabozantinib was consistent with that previously reported.
Implications of all the available evidence
The improvements in progression-free survival, overall survival, and objective response suggest that cabozantinib should be considered as a new treatment for previously treated patients with advanced renal cell carcinoma. Recently, the immune checkpoint inhibitor nivolumab also improved overall survival compared with everolimus in this population, but without improving progression-free survival. Future research on the optimal use of cabozantinib and other available treatments might help to provide maximum benefi t to patients with advanced renal cell carcinoma. randomisation schema. Study treatment was assigned centrally with an interactive voice and web response system. Study personnel did not have access to the master list of blocks or block sizes. Patients and investigators were not masked to study treatment to allow appropriate management of adverse events. Aggregate summaries of effi cacy data by treatment group were not done until the time of the primary progression-free survival analysis.
Procedures
Cabozantinib was given orally once a day at 60 mg and everolimus was given orally once a day at 10 mg. Everolimus was chosen as the comparator for cabozantinib since it is an accepted standard-of-care in second-line therapy for advanced renal cell carcinoma. 1, 14 Treatment modifi cations, including interruptions and dose reductions, were specifi ed to manage adverse events. Cabozantinib could be dose reduced to 40 mg and then 20 mg, and everolimus could be dose reduced to 5 mg and then 2·5 mg. Patients were allowed to continue study treatment beyond radiographic progression at the discretion of the investigator. On-study crossover between treatment groups was not permitted. Safety evaluations including physical examination, vital signs, laboratory tests, and adverse event assessments were done every 2 weeks for the fi rst 8 weeks and then every 4 weeks thereafter. ECG assessments were performed every 4 weeks for the fi rst 8 weeks and then every 12 weeks. A safety follow-up visit was scheduled 30 days after treatment discontinuation. Adverse events were assessed by investigators and graded according to Common Terminology Criteria for Adverse Events (CTCAE version 4.0). 15 Radiographic assessments by CT or MRI were done at screening and every 8 weeks for the fi rst 12 months and then every 12 weeks thereafter. Tumour response and progression were assessed according to RECIST (version 1.1) 12 by a masked centralised independent radiology review committee. Patients were followed for overall survival every 8 weeks.
Tumour tissue (archival or recently biopsied) was obtained at enrolment when available for immunohistochemistry analysis of MET protein levels. Formalinfi xed paraffi n embedded tumour blocks or freshly cut formalin-fi xed paraffi n embedded slides were analysed by LabCorp (Research Triangle Park, NC, USA) with the SP44 antibody (Spring Biosciences, Pleasanton, CA, USA). MET expression was defi ned as high versus low, based on a cutoff of 50% or higher of tumour tissue stained with an intensity of 2+ or 3+ by immunohistochemistry, according to published procedures. 16, 17 
Outcomes
The primary endpoint was progression-free survival by independent radiology review in the fi rst 375 randomised patients. Progression-free survival was defi ned as the time from randomisation to radiographic progression per RECIST or death from any cause. The secondary endpoints were overall survival, defi ned as the time from randomisation to death from any cause, and objective response per independent radiology review committee assessment, defi ned as the proportion of patients with a confi rmed complete or partial response per RECIST, assessed in all randomly assigned patients. Safety and tolerability were also assessed.
Statistical analysis
The study was designed to provide adequate power for both progression-free survival and overall survival analyses. For the primary endpoint of progression-free survival, the event-driven analysis (at the two-sided 5% α level) required 259 progression-free survival events. The secondary endpoints of overall survival (at the two-sided 4% α level) and objective response (at the two-sided 1% α level) were to be tested in all randomly assigned patients (per the intention-to-treat principle) at the time of the primary progression-free survival analysis only if the primary progression-free survival endpoint was signifi cant. For overall survival, assuming one interim analysis at the time of the primary endpoint analysis and a subsequent fi nal analysis, 408 deaths were required to provide 80% power to detect a hypothesised HR of 0·75 corresponding to an improvement in median survival from 15 months 18 to 20 months. With a planned average accrual rate of 32 patients per month and using a 1:1 treatment allocation ratio, 650 patients were required to observe 408 deaths within the planned study duration of 36 months. As the total sample size of 650 required to evaluate overall survival was much larger than needed to assess the primary endpoint of progression-free survival there was the possibility that patients with earlier onset of radiographic progression would be over-represented (and those with later onset of radiographic progression under-represented) among the planned 259 progressionfree survival events. To reduce this potential bias, the primary analysis of progression-free survival was prespecifi ed to occur when the required 259 events were observed in the fi rst 375 randomised patients, the size the study would have been without the overall survival endpoint. Supportive analyses of progression-free survival among all randomly assigned patients were also planned.
The planned interim analysis of overall survival (done at the time of the primary progression-free survival analysis with a data cutoff of May 22, 2015; minimum follow-up of 6 months) at that time did not meet the boundary for signifi cance (HR 0·67, 95% CI 0·51-0·89; p=0·005; 49% information fraction: critical p value ≤0·0019) defi ned by the Lan-DeMets O'Brien-Fleming alpha spending function. The results of the planned interim analysis of overall survival were made public in July, 2015, and were published in September, 2015. 11 The decision to conduct an unplanned second interim analysis was made by the funder in consultation with regulatory agencies. As a result, the analysis plan was revised in October, 2015, to include an unplanned second interim analysis of overall survival with a prospectively defi ned cutoff date of Dec 31, 2015, to provide a minimum of 13 months of follow-up from the last patient enrolled. At this analysis, the critical p value to achieve signifi cance from the alpha spending function was 0·0163 or lower.
We did hypothesis testing of overall survival and progression-free survival with the stratifi ed log-rank test with the randomisation stratifi cation factors. Median duration of progression-free survival and overall survival, corresponding 95% confi dence intervals, and landmark proportions were estimated by the Kaplan-Meier method. Hazard ratios (HRs) were estimated with a Cox regression model adjusted for the randomisation stratifi cation factors. The proportional hazards assumption was evaluated by visual inspection of log-log plots. A post-hoc sensitivity analysis of progression-free survival per independent radiology review committee among the 283 patients randomised after the fi rst 375 was conducted using the same methods as the primary analysis. Post-hoc analysis of patients who continued on study treatment for at least 2 weeks after radiographic progression as determined by the investigator evaluated post-progression changes in tumour status by two criteria: the proportion with at least one assessment of stable disease or partial response (from randomisation) after progression; and the proportion with at least one assessment in which the sum of target lesion diameters was lower than the pre-randomisation baseline value. Hypothesis testing for objective response was done with the Cochran-Mantel-Haenzel method, and confi dence intervals for proportions were calculated by the Clopper-Pearson method. All subgroup analyses of progressionfree survival and overall survival were prespecifi ed except for the subgroups based on receiving sunitinib or pazopanib as the only previous VEGFR tyrosine-kinase inhibitor. ECOG performance status was converted from Karnofsky status using ECOG 0 for Karnofsky status of 100% and 90% as ECOG 1 for Karnofsky status of 80% and 70%. Confi dence intervals and p values for subgroup analyses are considered descriptive. HRs reported for subgroup analyses are unadjusted. Safety analyses were limited to patients who received any amount of study treatment and analysed per protocol. All analyses were done with SAS (version 9.1 or higher).
This trial is registered at ClinicalTrials.gov, number NCT01865747.
Role of the funding source
The funder was involved in the study design, data collection, and analysis. The authors and the funder were involved in data interpretation. The steering committee members (TKC, BE, TP, and RJM) and DTA, CHH, CS, and GS had access to the raw data. The fi rst draft of the manuscript was written by TKC and RJM in collaboration with the funder. Medical writing support and cabozantinib 25 and everolimus were provided by the funder. All authors gave fi nal approval for submission and the corresponding author had the fi nal responsibility to submit for publication.
Results
Between Aug 8, 2013, and Nov 24, 2014, 658 patients were randomly assigned to receive cabozantinib (n=330) or everolimus (n=328; fi gure 1). Demographics and baseline characteristics were typical of patients with advanced renal cell carcinoma and were balanced between treatment groups (table 1). 11 As of Dec 31, 2015, the cutoff for the unplanned second interim analysis of overall survival, 74 (22%) of 330 patients in the cabozantinib group and 25 (8%) of 328 patients in the everolimus group remained on study treatment. The median duration of follow-up for overall survival and safety was 18·7 months (IQR 16·1-21·1) in the cabozantinib group and 18·8 months (16·0-21·2) in the everolimus group. The second interim analysis of overall survival included 320 deaths, representing 78% of the 408 deaths planned for the prespecifi ed fi nal analysis of overall survival: 140 (42%) patients died in the cabozantinib group and 180 (55%) died in the everolimus group. Survival status as of the cutoff date was determined for most (98%) of the 658 randomly assigned patients.
Treatment with cabozantinib signifi cantly increased overall survival compared with that in patients treated with everolimus (fi gure 2). The median overall survival was 21·4 months (95% CI 18·7-not estimable) in the cabozantinib group compared with 16·5 months (14·7-18·8) in the everolimus group. The HR was 0·66 (95% CI 0·53-0·83; p=0·00026), which met the criterion for signifi cance (p≤0·0163) from the prespecifi ed alpha spending function. A log-log plot of the survivor functions (appendix p 6) had reasonably parallel lines, supporting the assumption of proportional hazards.
Kaplan-Meier landmark estimates at 6, 12, 18, and 24 months showed that at each timepoint the proportion of patients estimated to be alive was greater in the cabozantinib group compared with the everolimus group (appendix p 6). All subgroup analyses of overall survival were consistent with the results for the overall population (fi gure 3). The appendix shows Kaplan-Meier plots of overall survival for patients with high and low tumour MET expression status (p 7).
The data cutoff for progression-free survival and objective response analyses in all randomised patients was the same as for the primary progression-free survival analysis (May 22, 2015) with a median duration of follow-up of 11·4 months (IQR 8·8-13·7) in the cabozantinib group and 11·5 months (8·6-13·9) in the everolimus group. 11 180 events occurred in the cabozantinib group and 214 in the everolimus group. The analysis of progression-free survival per independent radiology review done in all 658 randomly assigned patients showed improved progression-free survival with . The median progression-free survival was 7·4 months (95% CI 6·6-9·1) in the cabozantinib group versus 3·9 months (3·7-5·1) in the everolimus group. These results were consistent with the previously reported primary endpoint of progression-free survival done in the fi rst 375 randomly assigned patients 11 and an additional post-hoc sensitivity analysis of progression-free survival per independent radiology review done in the 283 patients not included in the primary progression-free survival analysis (HR 0·44 [95% CI 0·31-0·61]). Results for progression-free survival per investigator assessment were similar to those shown by the independent radiology review committee (appendix p 9). Subgroup analyses of progression-free survival per independent radiology review were also consistent with the results for the overall population (fi gure 3). The proportion of patients who achieved an objective response per independent radiology review in all 658 randomly assigned patients was 57 (17% [95% CI [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] ; 57 partial responses) of 330 in the cabozantinib group and 11 (3% [2-6]; 11 partial responses) of 328 in the everolimus group (p<0·0001; appendix p 9). Results for tumour response per investigator assessment were similar to those established by the independent radiology review committee (appendix p 9).
As of the May 22, 2015, cutoff date, the proportions of patients continuing study treatment for at least 2 weeks after radiographic progression as assessed by the investigator were similar between groups, 74 (38%) of 193 who progressed on cabozantinib and 71 (31%) of 226 who progressed on everolimus). Post-hoc analyses of response for these patients showed that fi ve (7%) of 74 patients in the cabozantinib group and six (8%) of 71 in the everolimus group had stable disease or a partial response after the initial radiographic progression. Additionally, 34 (46%) of 74 patients in the cabozantinib group and 15 (21%) of 71 in the everolimus group had at least one assessment in which the sum of target lesion diameters was lower than the pre-randomisation baseline value.
As of the Dec 31, 2015, the cutoff for the overall survival analysis, the median duration of exposure was 8·3 months (IQR 4·2-14·6) in patients given cabozantinib (n=331) and 4·4 months (1·9-8·6) in patients given everolimus (n=322). Dose reductions occurred for 206 (62%) patients in the cabozantinib group and 80 (25%) patients in the everolimus group. The median daily dose was 43 mg (IQR 36-56) cabozantinib and 9 mg (7-10) everolimus. Treatment discontinuation because of an adverse event not related to disease progression was recorded in 40 (12%) of 331 patients in the cabozantinib group and 34 (11%) of 322 patients in the everolimus group. The most frequent reason for treatment discontinuation in both groups was disease progression (fi gure 1). Similar proportions of patients in the everolimus group and the cabozantinib group were reported to have received subsequent systemic anticancer treatment after study treatment discontinuation (181 [55%] vs 165 [50%]; appendix p 8).
The overall incidence of adverse events irrespective of causality was 100% for both groups (331 of 331 patients treated with cabozantinib and 321 of 322 treated with everolimus). We recorded grade 3 or 4 adverse events in 235 (71%) patients treated with cabozantinib and 193 (60%) treated with everolimus ( (appendix p 10). One death was assessed as treatment related in the cabozantinib group (death; not otherwise specifi ed) and two were assessed as treatment-related in the everolimus group (one aspergillus infection and one pneumonia aspiration).
Discussion
Our fi ndings showed a signifi cant overall survival benefi t for cabozantinib treatment compared with everolimus treatment in patients with previously treated advanced renal cell carcinoma. Progression-free survival was also signifi cantly improved in the cabozantinib group versus the everolimus group and we recorded a higher proportion of patients with an objective response in the cabozantinib group compared with the everolimus group. The progression-free survival results in all randomly assigned patients were consistent with the results previously reported for the fi rst 375 randomly assigned patients (the primary endpoint of the study). 11 Objective tumour response per independent radiology review was also consistent with the previously reported results for the fi rst 375 randomly assigned patients. The updated safety profi le of cabozantinib was similar to that previously reported at the earlier data cutoff for this study. 11 The most common adverse events were typical of those recorded with other VEGFR tyrosinekinase inhibitors in patients with renal cell carcinoma. 19 The adverse event profi le for everolimus was similar to that reported in other renal cell carcinoma studies. 20 Adverse events were managed with dose modifi cations and supportive care in both treatment groups. Although the frequency of dose reductions was higher in the cabozantinib group, the number of treatment discontinuations due to adverse events was similar in both groups, suggesting that dose modifi cations were eff ective in minimising or preventing treatment-associated discontinuations.
The results for overall survival and progression-free survival in all subgroups were consistent with those for the overall population, including those defi ned by the prespecifi ed stratifi cation factors (MSKCC risk group and number of previous VEGFR tyrosine-kinase inhibitors). The most common previous treatments were sunitinib and pazopanib, consistent with standard clinical practice. 1 Outcomes for patients refractory to fi rst-line VEGFR tyrosine-kinase inhibitor treatment are not available because this information was not collected. The eff ects of cabozantinib on overall survival and progression-free survival in patients with bone metastases, which are associated with a poor prognosis, 21 are consistent with reported eff ects of cabozantinib on bone metastases in both clinical and preclinical studies, 22, 23 and warrant further investigation into the mechanisms underlying the activity of cabozantinib in bone.
The proportions of patients continuing study treatment for at least 2 weeks after radiographic progression were similar between groups. The proportions of patients who received subsequent anticancer treatment after study treatment discontinuation were also similar between the treatment groups. Therefore, these factors are unlikely to have biased the results of overall survival towards one treatment group. Additionally, treatment crossover was not allowed after determination of the primary endpoint of progression-free survival, enabling robust assessment of overall survival.
Although the study used an open-label design, bias was minimised for the primary endpoint of progression-free survival and secondary endpoint of objective response by evaluation of radiographic assessments by a masked central independent radiology review committee. Additionally, radiographic assessments were continued beyond investigator-determined progression to reduce missing data arising from discordance between the investigator and the independent radiology review committee about the date of progression. An advantage of open-label design is appropriate management of adverse eff ects in both study groups.
High MET expression in patients with advanced renal cell carcinoma has been associated with both a poor prognosis and prior exposure to VEGFR tyrosine-kinase inhibitors, and in preclinical models is associated with resistance to VEGFR tyrosine-kinase inhibitor treatment. 5, 8, 9, 24 Therefore, because cabozantinib targets receptor tyrosine kinases including MET, we investigated MET expression by immunohistochemistry as a potentially predictive biomarker for cabozantinib in this study population. However, the results suggest that the MET expression level might not aff ect treatment outcomes with cabozantinib in this patient population, which might refl ect the broader target profi le of cabozantinib. A limitation of this analysis was that archival tumour tissue was used in most cases rather than a fresh biopsy obtained before study treatment initiation, which could have resulted in MET expression values that were not contemporaneous with the disease state during study treatment. Additionally, about one third of randomly assigned patients had an unknown MET status because archival tumour tissue was not available.
Our results support the hypothesis that the target profi le of cabozantinib, which inhibits MET and AXL in addition to VEGF receptors, might help to overcome resistance to VEGFR inhibition. [5] [6] [7] [8] [9] [10] This view is supported by the low incidence of refractory disease recorded, with only 12% of patients experiencing progressive disease as a best response with cabozantinib treatment. Furthermore, the eff ects of cabozantinib were consistently noted irrespective of the duration of the fi rst previous VEGFR tyrosine-kinase inhibitor treatment. The results also suggest that sequenced VEGFR inhibition can be benefi cial for the treatment of advanced renal cell carcinoma, which has also been suggested by the report of a phase 2 study with levantinib. 25 Additional studies are necessary to clearly defi ne the roles of MET, AXL, and other targets beyond VEGFR in the clinical activity recorded with cabozantinib in patients with advanced renal cell carcinoma. Future studies could also include more detailed assessment of response to fi rst-line therapy and tumour biopsies at the time of progression to better defi ne the mechanisms of resistance and the possible benefi ts of sequenced VEGFR inhibition.
Several VEGFR tyrosine-kinase inhibitors have previously been approved for the treatment of metastatic renal cell carcinoma, and these comprise the mainstay of present day treatment. Regulatory approval for each of these (sunitinib, sorafenib, pazopanib, and axitinib) was based on an improvement in progression-free survival over control groups of cytokine (interferon), placebo, or sorafenib in a randomised phase 3 trial. [26] [27] [28] [29] The mTOR inhibitor everolimus, which was used as the comparator arm in this study, was also approved based on improved progression-free survival when compared to placebo. 30 None of the pivotal phase 3 trials for these previously approved agents showed a signifi cant benefi t in overall survival. Improvement in overall survival remains the gold standard as an endpoint for representing clinical benefi t in patients. It is therefore notable that in this study cabozantinib treatment resulted in a benefi t in overall survival in addition to improved progression-free survival and objective response compared with everolimus in patients who had progressed on standard VEGFR tyrosine-kinase inhibitor treatments. The diff erence in overall survival between cabozantinib and everolimus highlights the clinical activity of cabozantinib in advanced renal cell carcinoma. Adverse events that were reported as grade 1-2 in at least 10% of the patients in either study group are shown, irrespective of whether the event was considered by the investigator to be related to the study treatment. All grade 3, 4, and 5 events are listed in the appendix (p 10). One treatment-related death occurred in the cabozantinib group (death; not otherwise specifi ed) and two occurred in the everolimus group (one aspergillus infection and one pneumonia aspiration). Patients are counted once at the highest grade for each preferred term. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). 
